HPOL-B Stock Analysis: HEXPOL (publ) | ST
Specialty Chemicals | ST, Sweden | Market Cap: 24.472m SEK | 12M Return: -20.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 27.5M
EPS Trend: -95.5%
Qual. Beats: 0
Rev. Trend: -98.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
HEXPOL AB (publ) is a Swedish specialty chemicals and engineered products manufacturer headquartered in Malmö, operating globally across Europe, the Americas, and Asia. The company runs two business segments: HEXPOL Compounding, which produces natural and synthetic rubber compounds, thermoplastic elastomer compounds, and thermoplastic compounds under brands such as HEXFLAME, Dryflex, Mediprene, and RheTech; and HEXPOL Engineered Products, which supplies finished gaskets and seals under the Gislaved Gummi brand and wheels under the Stellana brand. Founded in 1893 and formerly known as Hexagon Polymers AB before adopting its current name in May 2008, HEXPOL serves a broad B2B customer base spanning automotive, aerospace, energy, construction, oil and gas, medical equipment, and consumer products manufacturers.
As a mid-cap player in the specialty chemicals sub-industry within the Materials sector, HEXPOL follows a diversified industrial supplier model, distributing its polymer-based inputs and finished components across more than a dozen end markets, which reduces reliance on any single industry. Its dual structure of custom compounding and branded engineered products positions it as both a raw-materials provider to manufacturers and a producer of finished components, giving it exposure to both upstream and downstream value chains in rubber and plastics.
- Automotive demand softness pressures compounding segment volumes
- Raw material cost volatility squeezes polymer compound margins
- M&A pipeline expansion accelerates compounding segment growth
| Net Income: 1.85b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 0.22 > 1.0 |
| NWC/Revenue: -1.70% < 20% (prev -1.36%; Δ -0.34% < -1%) |
| CFO/TA 0.10 > 3% & CFO 2.58b > Net Income 1.85b |
| Net Debt (3.26b) to EBITDA (3.23b): 1.01 < 3 |
| Current Ratio: 0.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (344.4m) vs 12m ago 0.00% < -2% |
| Gross Margin: 21.03% > 18% (prev 21.21%; Δ -0.19% > 0.5%) |
| Asset Turnover: 76.59% > 50% (prev 85.02%; Δ -8.42% > 0%) |
| Interest Coverage Ratio: 21.40 > 6 (EBIT TTM 2.65b / Interest Expense TTM 124.0m) |
| A: -0.01 (Total Current Assets 7.61b - Total Current Liabilities 7.92b) / Total Assets 24.7b |
| B: 0.48 (Retained Earnings 11.8b / Total Assets 24.7b) |
| C: 0.11 (EBIT TTM 2.65b / Avg Total Assets 24.4b) |
| D: 1.53 (Book Value of Equity 15.0b / Total Liabilities 9.77b) |
| Altman-Z'' = 3.80 = AA |
| DSRI: 1.13 (Receivables 3.65b/3.53b, Revenue 18.7b/20.5b) |
| GMI: 1.01 (GM 21.21% / 21.03%) |
| AQI: 0.99 (AQ_t 0.54 / AQ_t-1 0.55) |
| SGI: 0.91 (Revenue 18.7b / 20.5b) |
| TATA: -0.03 (NI 1.85b - CFO 2.58b) / TA 24.7b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 09, 2026, the stock is trading at SEK 70.60 with a total of 212,039 shares traded. Over the past week, the price has changed by -2.69%, over one month by -4.59%, over three months by +0.57% and over the past year by -20.41%.
Current recommended Stop Loss: 68.50 (which is 3% or 1.3 ATR below the current price).
HEXPOL (publ) has no consensus analysts rating.
P/E Trailing = 13.2556
P/E Forward = 18.3824
P/S = 1.3079
P/B = 1.7169
P/EG = 2.729
Revenue TTM = 18.7b SEK
EBIT TTM = 2.65b SEK
EBITDA TTM = 3.23b SEK
Long Term Debt = 338.0m SEK (from longTermDebtTotal, last fiscal year)
Short Term Debt = 4.46b SEK (from shortTermDebt, last quarter)
Debt = 5.23b SEK (from shortLongTermDebtTotal, last quarter) + Leases 428.0m
Net Debt = 3.26b SEK (calculated: Debt 5.23b - CCE 1.97b)
Enterprise Value = 27.7b SEK (24.5b + Debt 5.23b - CCE 1.97b)
Interest Coverage Ratio = 21.40 (Ebit TTM 2.65b / Interest Expense TTM 124.0m)
EV/FCF = 11.74x (Enterprise Value 27.7b / FCF TTM 2.36b)
FCF Yield = 8.52% (FCF TTM 2.36b / Enterprise Value 27.7b)
FCF Margin = 12.63% (FCF TTM 2.36b / Revenue TTM 18.7b)
Net Margin = 9.88% (Net Income TTM 1.85b / Revenue TTM 18.7b)
Gross Margin = 21.03% ((Revenue TTM 18.7b - Cost of Revenue TTM 14.8b) / Revenue TTM)
Gross Margin QoQ = 21.54% (prev 19.58%)
Tobins Q-Ratio = 1.12 (Enterprise Value 27.7b / Total Assets 24.7b)
Interest Expense / Debt = 2.37% (Interest Expense 124.0m / Debt 5.23b)
Taxrate = 26.93% (681.0m / 2.53b)
NOPAT = 1.94b (EBIT 2.65b * (1 - 26.93%))
Current Ratio = 0.96 (Total Current Assets 7.61b / Total Current Liabilities 7.92b)
Debt / Equity = 0.35 (Debt 5.23b / totalStockholderEquity, last quarter 15.0b)
Debt / EBITDA = 1.01 (Net Debt 3.26b / EBITDA 3.23b)
Debt / FCF = 1.38 (Net Debt 3.26b / FCF TTM 2.36b)
Total Stockholder Equity = 14.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.56% (Net Income 1.85b / Total Assets 24.7b)
RoE = 13.00% (Net Income TTM 1.85b / Total Stockholder Equity 14.2b)
RoCE = 18.22% (EBIT 2.65b / Capital Employed (Equity 14.2b + L.T.Debt 338.0m))
RoIC = 9.53% (NOPAT 1.94b / Invested Capital 20.3b)
WACC = 7.42% (E(24.5b)/V(29.7b) * Re(8.63%) + D(5.23b)/V(29.7b) * Rd(2.37%) * (1-Tc(0.27)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 44.72 | Cagr: 0.00%
[DCF] Terminal Value 76.07% ; FCFF base≈2.32b ; Y1≈2.42b ; Y5≈2.78b
[DCF] Fair Price = 120.3 (EV 42.9b - Net Debt 3.26b = Equity 39.6b / Shares 329.7m; r=8.35% [WACC [floored]]; 5y FCF grow 4.93% → 2.50% )
EPS Correlation: -95.49 | EPS CAGR: -12.19% | SUE: 0.0 | # QB: 0
Revenue Correlation: -98.42 | Revenue CAGR: -6.69% | SUE: -0.20 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.48 | Chg30d=-0.67% | Revisions=-25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=1.44 | Chg30d=+0.70% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=5.63 | Chg30d=+1.37% | Revisions=+0% | GrowthEPS=-0.2% | GrowthRev=-1.7%
EPS next Year (2027-12-31): EPS=6.13 | Chg30d=-0.26% | Revisions=+0% | GrowthEPS=+8.9% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: +0% (up=3, down=3)